Osteoporosis in RETT Syndrome

Study Overview
=================
Brief Summary
-----------------
Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown. Mutations in the MECP2 gene are found in 95% of RETT patients and preliminary experimental studies have shown that this can lead to abnormal expression of the gene that codes for osteoprotegerin, a protein implicated in bone remodelling by interacting with RANK-ligand. In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes: Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D satus) evaluation of the mineral density at the lumber spine using DEXA measuring concentrations of osteoprotegerin and RANK-ligand

Detailed Description
-----------------
Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed to osteoporosis then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown. Mutations in the MECP2 gene are found in 95% of RETT patients. Preliminary experimental studies on the transcriptional consequences of MECP2 mutations showed that the expression of 13 genes were significantly dysregulated and one of them is the gene that codes for osteoprotegerin, a soluble receptor that binds to RANK-ligand. RANK-ligand is an osteoclastic differentiation factor expressed by osteoblasts. In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes: Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D status) evaluation of the mineral density at the lumber spine using DEXA measuring concentrations of osteoprotegerin and RANK-ligand

Official Title
-----------------
Osteoporosis in RETT Syndrome. Understanding the Mechanisms and Identification of Biomarkers.

Conditions
-----------------
RETT Syndrome With Proven MECP2 Mutation

Intervention / Treatment
-----------------
* Other: biological markers and evaluation of the mineral density at the lumber spine using DEXA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RETT syndrome MECP2 mutation Exclusion Criteria: no identified MECP2 mutation history of drugs that interfere with bone metabolism

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: RETT patients<br> | Other: biological markers and evaluation of the mineral density at the lumber spine using DEXA<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| osteoporosis in RETT patients | Correlation between clinical/biological risk factors and mineral density and osteoporosis in RETT patients | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biological Mechanisms of osteoporosis | RANK-ligand and osteoprotegerin concentrations | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RETT syndrome, MECP2, Osteoporosis, RANK-ligand, osteoprotegerin